No. A peptide COA that says “99% purity” does not establish that a product is safe to inject, contains the labeled amount, or works for a health goal. A certificate of analysis reports particular tests on a particular sample. Its meaning depends on the methods, results and connection to the material being discussed.
This guide answers recurring questions about purity-only reports, missing sterility results and “third-party tested” claims. This guide is educational, not a recommendation to use peptides. It explains evidence, not how to choose, purchase, prepare or use research peptides. Sources checked November 16, 2026. No clinician review is claimed.
What does 99% purity actually mean?
The first question is: 99% of what, measured how? A chromatographic purity percentage is not automatically the percentage of all the powder in a vial that is the named peptide. It is a result calculated under a defined analytical method. Treating it as a universal safety score changes the question the test answered.
In an original study of peptide reference standards, USP and MHRA researchers used multiple methods to establish identity and assign content. Their mass-balance approach accounted for peptide impurities, water, counterions and residual solvents; assigning peptide content to a vial was a separate step. They also explain why some amino-acid differences require additional characterization. Original reference-standard study
So “high purity,” “correct identity” and “the stated amount is present” are related quality questions, not interchangeable answers. Nor should an exact molecular-mass match be treated as complete proof of every structural detail.
Which questions are separate?
FDA’s description of investigational-drug quality information separates identity, strength, purity and stability. For injectable products, it also identifies sterility, pyrogenicity, endotoxin levels and particulate matter. That framework illustrates why a single purity result cannot answer all the questions below. It is not a consumer checklist that certifies an online vial. FDA chemistry, manufacturing and control information
- Identity: What evidence supports the claimed substance?
- Content or strength: How much of the substance was measured?
- Purity and impurities: Which impurities could the method detect, and which were evaluated?
- Microbiological quality: What distinct testing addresses microorganisms and endotoxins?
- Stability: What supports quality over time in the relevant formulation and container?
“Not shown” is not the same as “passed.” It is also not proof that the sample failed: the honest conclusion is that the report does not establish that result.
Does purity prove sterility or low endotoxin?
No. These require their own evidence. Sterility concerns viable microorganisms; endotoxin testing addresses bacterial endotoxins. FDA maintains separate guidance on pyrogen and endotoxin testing, including methods and acceptance criteria for appropriate components and finished products. A purity percentage does not replace those assessments. FDA endotoxin-testing guidance
Even a passing sterility test is not a guarantee about every unit. In a 2026 manufacturing warning letter, FDA explained that the tested sample is typically small relative to a batch and may miss sporadic non-sterility. Process controls and container integrity matter too. This is a general limitation of sampling, not a claim that a particular peptide supplier has failed. FDA explanation of sterility-test limitations
A real example: a COA did not make an ingredient suitable for injection
FDA investigated adverse-event reports involving compounded intravenous glutathione in 2019. A translated manufacturer COA accompanied the ingredient, but the manufacturer said the material was intended for dietary supplements, not sterile drugs. FDA tested samples and found excessive bacterial endotoxin.
The lesson is narrower and more useful than “all COAs are worthless”: intended use, manufacturing controls and the actual tests matter. FDA explicitly warned that testing alone should not be relied upon to ensure drug quality. This incident does not establish the contamination rate of other products. FDA investigation and findings
Does “third-party tested” mean the whole batch was checked?
The phrase alone does not identify the test panel, sampling plan or link to a finished vial. FDA’s API manufacturing guidance describes a COA with the material name, batch number, tests, acceptance limits, numerical results where applicable, date and authorized quality-unit signature. Traceability to the original manufacturer also matters. A logo or a screenshot without that context cannot supply the missing information. FDA Q7A, certificates of analysis
A report on bulk ingredient and a report on a finished product do not have identical scope. FDA has highlighted patient risks from inadequate supply-chain transparency and repackaging, including an ingredient labeled as one drug that testing identified as another. FDA supplier-quality alert
How to read a purity-only report without overclaiming
Imagine a report listing a batch identifier and one HPLC purity result of 99%, with no other results displayed. A careful summary is: “This document reports a purity result for the identified sample under the stated method.” It is not: “Every vial is sterile, has the labeled amount and is safe for human use.”
When discussing a report with a pharmacist or clinician, separate three columns in your notes: reported result, test and sample it refers to, and questions not answered. Mark missing information as unknown rather than giving the product an overall safety score. This is a reading aid, not a product-verification or treatment decision tool.
Can a COA prove FDA approval or clinical effectiveness?
No. Laboratory quality results are not a clinical trial or a drug-approval decision. FDA explains that compounded drugs are not FDA-approved and do not undergo its premarket review for safety, effectiveness or quality, even though compounding can meet particular medical needs. FDA compounding questions and answers
Keep the two evidence trails separate: what is known about a preparation’s quality, and what human studies actually show for a molecule, route and outcome. Our peptide evidence library addresses the second question. Neither a favorable research result nor a purity certificate authenticates an unrelated vial.